Lawmakers pressure PTC on Emflaza price by Eric Sagonowsky Thursday, March 23, 2017 When PTC agreed to buy Marathon's Emflaza last week, it inherited congressional scrutiny on the drug's price, originally set at a much-lambasted $89,000.
Marathon makes surprise deal to sell Emflaza for $140M-plus by Tracy Staton Thursday, March 16, 2017 Marathon Pharma has scored a quick payoff by selling Emflaza to PTC Therapeutics in a deal potentially worth more than $190 million.
Lawmakers pull FDA into the dock over Marathon's Emflaza nod by Eric Sagonowsky Wednesday, March 15, 2017 Sen. Bernie Sanders and Rep. Elijah Cummings have 'serious questions' for the FDA after its approval of Marathon's controversial Duchenne med Emflaza.
Eight senators pile on to Marathon's $89K Emflaza price tag by Eric Sagonowsky Monday, March 6, 2017 Marathon’s Emflaza pricing remains in an unwelcome spotlight as eight more senators zero in on the company and its newly approved, $89,000 DMD med.
Marathon halts launch of DMD drug as $89K price attracts congressional heat by Eric Sagonowsky Monday, February 13, 2017 A fresh pharma pricing controversy has led to congressional scrutiny for Marathon Pharma.
